Video: Every Case Tells a Story| Webinar: ACR/CHEST ILD Guidelines in Practice

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • QA/QI
    • Technology
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

The Impact of U.S. Supreme Court Decisions on Medical Affairs, Healthcare Policy

Simon M. Helfgott, MD  |  Issue: October 2016  |  October 11, 2016

Being a small state, Vermont has experimented with innovations in the healthcare marketplace. For example, the state has toyed with the idea of a single-payer system, and more recently it mandated that all self-insured companies must submit their data to a state registry that would allow for a more thorough analysis of costs and trends. One company, Liberty Mutual Insurance, objected, stating that federal laws, such as the Employment Retirement Income Security Act (ERISA), invalidate any state claims to such information. The case, known as Gobeille v. Liberty Mutual Insurance Co., was argued in the Supreme Court, where the justices sided with the insurer’s arguments.12 This verdict was a blow to efforts to pry open cost transparency in our bloated system. With self-insured companies providing coverage for nearly two-thirds of the population, this data collection is critical. At this point, it would take an act of Congress to modify ERISA to allow this to happen. Don’t hold your breath.

Live Free or What?

The fierce patriotism of Vermont’s neighbor, New Hampshire, is summarized by its motto, live free or die. Perhaps Vermonters should consider the maxim, live free or litigate—an activity as American as apple pie.

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

Simon M. Helfgott, MDSimon M. Helfgott, MD, is associate professor of medicine in the Division of Rheumatology, Immunology and Allergy at Harvard Medical School in Boston.

References

  1. Luxenberg S. A likely story … and that’s precisely the problem. The Washington Post. 2005 Apr 17.
  2. Pear R. Four words that imperil health care law were all a mistake, writers now say. The New York Times. 2015 May 25.
  3. Jacoby J. US legal bubble can’t pop soon enough. Boston Globe. 2014 May 9.
  4. Nix E. 7 things you might not know about the U.S. Supreme Court. History (A&E Networks). 2013 Oct 8.
  5. Supreme Court building. Architect of the Capitol. 2016 Apr 4.
  6. Sherkow J. Are genes patentable? A summary of the Supreme Court case. 2013 Apr 16.
  7. Watson J, Baker TA, Bell SP, et al. Molecular Biology of the Gene, 6th ed. Cold Spring Harbor Laboratory Press: Cold Spring Harbor, N.Y., 2008.
  8. Conley J. Myriad, finally: Supreme Court surprises by not surprising. Genomics Law Report. 2013 Jun 18.
  9. Board of Trustees of the Leland Stanford Junior University v. Roche Molecular Systems (No. 09-1159). Argued Feb. 28, 2011. Decided June 6, 2011. Legal Information Institute.
  10. Sorrell, attorney general of Vermont, et al. v. IMS Health Inc. et al. (No. 10–779). Argued April 26, 2011. Decided June 23, 2011.
  11. David S, Rosenbaum S. Wyeth v Levine: Implications for public health policy and practice. Public Health Rep. 2010 May–Jun; 125(3): 494–497.
  12. Brown EF, King J. The consequences of Gobeille v. Liberty Mutual for health care cost control. Health Affairs Blog (Project HOPE: The People-to-People Health Foundation Inc.). 2016 Mar 10.

Page: 1 2 3 4 5 6 | Single Page
Share: 

Filed under:OpinionRheuminationsSpeak Out Rheum Tagged with:Affordable Care Act (ACA)BRCADNAgeneHealth carejudiciarylawsLegislationmedicalSupreme CourtVermont

Related Articles

    Cliff Diving: Evergreening & Other Oddities

    September 5, 2022

    The glassblowers were in revolt. The island of Murano, in the 13th century, was a perfect home for the glassblowing industry. Connected to Venice through a system of bridges, Murano was surrounded by waters that protected the city from the furnaces that fueled the glassblowers’ craft. The Republic of Venice dominated trade throughout the Mediterranean,…

    U.S. Supreme Court Upholds Obamacare Insurance Subsidies

    June 25, 2015

    WASHINGTON (Reuters)—The U.S. Supreme Court preserved President Barack Obama’s signature healthcare law on Thursday, upholding crucial tax subsidies while turning aside a conservative legal challenge that could have doomed the law. “After more than 50 votes in Congress to repeal or weaken this law, after a presidential election based in part on preserving or repealing…

    Technological Advances Linked to Medical Misadventures

    April 15, 2016

    For keen students of American politics, the unending intrigue of the 2016 presidential race has been riveting. With an assemblage of aspiring candidates that, at its start, included a bevy of U.S. senators and former governors, a media-savvy real estate mogul, a renowned Hopkins neurosurgeon and an ophthalmologist, political junkies among us have feasted on…

    U.S. Supreme Court to Hear Dispute Over Biologic Drug Sales

    January 15, 2017

    NEW YORK (Reuters)—The U.S. Supreme Court on Friday agreed to hear a dispute over whether companies that make copycat versions of biologic drugs must wait six months after winning federal approval to begin selling them. The justices will take up an appeal by Novartis AG of a 2015 federal appeals court decision that prevented the…

  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences